Gabapentin Capsule
Product Images NDC 80425-0128

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 80425-0128). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Pharmacy Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin 100mg Cap Qty 60 Ndc 80425 0128

Gabapentin 100 mg oral capsules label from Advanced Rx Pharmacy of Tennessee, LLC. The label indicates a bottle containing 60 capsules, with the NDC number 80425-0128, lot number G10060723, and an expiration date of 7/31/2023. Storage instructions specify room temperature 20°-25°C (68°-77°F). The label also includes a barcode and cautions regarding federal law restrictions.*

FDA Label Image

Gabapentin 100mg Cap Qty 90 Ndc 80425 0128

The label for Gabapentin 100 mg capsules from Advanced Rx Pharmacy of Tennessee, LLC, includes details for a 90-capsule package. It features the proprietary and generic name Gabapentin, NDC number 80425-0128, lot number 90GP100324, expiration date 3/31/2024, storage instructions at room temperature, and a barcode.*

FDA Label Image

Structure

Chemical structure of gabapentin, showing a cyclohexane ring bonded to two side chains: one with an amino group (CH2NH2) and another with a carboxyl group (CH2CO2H).*

FDA Label Image

Image 0

A formula showing the calculation for creatinine clearance (CLCr), which involves age, weight, serum creatinine levels, and a correction factor for female patients. This calculation is relevant to clinical pharmacology but does not contain branding or product-specific information.*

FDA Label Image

Image 1

A line graph depicting mean pain scores over a 7-week period comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The graph includes a 3-week dose titration period followed by a 4-week fixed dose period, showing pain score trends for each treatment group across baseline through week 7.*

FDA Label Image

Image 3

Bar chart titled 'Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and Gabapentin (GBP) doses in two studies. Study 1 shows 12% responders for PBO and 29% for GBP 3600 mg. Study 2 shows 14% responders for PBO, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance indicated by p-values less than 0.01 and 0.001.*

FDA Label Image

Image0

A line graph showing mean pain scores over an 8-week period comparing placebo and Gabapentin at 3600 mg/day. The x-axis represents weeks, divided into a 4-week dose titration period and a 4-week fixed dose period. The y-axis represents mean pain scores, ranging from 0 to 10. Gabapentin shows a decline in pain score over time, while placebo scores remain relatively stable.*

FDA Label Image

Image4

A scatter plot comparing percentage differences by daily dose in milligrams for three studies labeled 'a', 'b', and 'c'. The x-axis represents daily dose (mg) from 600 to 1800, and the y-axis shows difference (%) from 2 to 22. The plot includes data points for each study at various doses, marked with distinct square symbols and corresponding letters.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.